<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-MTKSK205</identifier><date>2023</date><creator>Kokondoska Grgič, Vesna</creator><creator>Sinreih, Maša</creator><creator>Zottel, Alja</creator><relation>documents/doc/M/URN_NBN_SI_doc-MTKSK205_001.pdf</relation><relation>documents/doc/M/URN_NBN_SI_doc-MTKSK205_001.txt</relation><format format_type="issue">5</format><format format_type="volume">74</format><format format_type="type">article</format><format format_type="extent">str. 362-370</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">178586627</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-MTKSK205</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">3D celični model</subject><subject language_type_id="slv">rak</subject><subject language_type_id="slv">sferoidi</subject><subject language_type_id="slv">testiranje zdravilnih učinkovin</subject><title>3D celični modeli in njihova uporaba pri testiranju protirakavih zdravilnih učinkovin</title><title>3D cell models and their use in testing of anticancer drugs</title></Record>